Jaguar Gene Therapy LLC, a startup reuniting former Avexis Inc. executives to develop a portfolio of potential treatments for severe genetic diseases, announced its public debut Feb. 25 with more than $40 million in series A financing from co-creator Deerfield Management.
RNA has “huge potential” as a therapeutic modality and is beginning to deliver on that potential. But “manufacturing RNA has issues in production, delivery and performance,” Thomas Barnes told BioWorld. Barnes is the CEO of startup Orna Therapeutics LLC, which has the goal of addressing those issues with oRNA, an engineered form of circular RNA.
Ensoma Inc., a gene therapy startup working to drastically simplify the production and delivery of genomic medicines, announced itself Feb. 11 with a $70 million series A financing plus a strategic collaboration with Takeda Pharmaceutical Co. Ltd., which licensed vectors from the company for up to five rare disease targets in a deal that could deliver as much as $1.25 billion in potential payouts. Ensoma's co-founder and seed investor, 5AM Ventures, led the financing. Takeda took a $10 million equity stake as part of the round.
Boston-based Nirogy Therapeutics Inc.’s $16.5 million series A round is meant to enable a pipeline of small-molecule drugs targeting the solute carrier family of transporter proteins (SLCTs) embedded in the cell membrane, and let the firm bring its front oncology runner to the clinic in 2022.
San Diego area startup Endeavor Biomedicines Inc. launched in January 2021, with a $62 million series A financing from Omega Funds, Longitude Capital and its own management team. The company is working on one asset, ENV-101 or taladegib, a small-molecule inhibitor targeting the Hedgehog pathway, which it plans to develop for the treatment of idiopathic pulmonary fibrosis (IPF).
LONDON – Theolytics Ltd. raised $6.8 million in a series A round to further develop its platform technology and advance the lead oncolytic virus program toward the clinic.
Lexeo Therapeutics Inc., a New York-based startup initially advancing clinical and near-clinical stage candidates for Friedreich’s ataxia, CLN2 and Alzheimer's diseases, has raised an $85 million series A financing round led by Longitude Capital and Omega Funds. Founded by gene therapy development veteran Ronald Crystal, the company is led by CEO Nolan Townsend, the former head of Pfizer Inc.'s rare disease efforts in North America.
Abcuro Inc. raised $42 million in a series A-1 round to progress preclinical programs in autoimmune disease and cancer involving a largely overlooked immune checkpoint receptor, killer cell lectin-like receptor G1 (KLRG1).
Iconovir Bio Inc., of San Diego, raised $77 million in a series A financing to develop differentiated oncolytic virus candidates the company said it believes could potentially be I.V.-administered, tumor-selective and could broadly infect tumor cells.
Scineuro Pharmaceuticals, based in Shanghai and Philadelphia, launched with a $100 million series A financing to focus on tackling central nervous system diseases. CEO Min Li told BioWorld the startup is “building a CNS portfolio through a combination of internal R&D and strategic collaborations.” Lilly Asia Ventures Fund and Arch Venture Partners co-led the round.
RSS
